Brolucizumab for CNV Associated With Pathologic Myopia (COASTUAbaCNV)
Collaborative Ocular Antiangiogenic Study of Ukraine. Multicentral, Open-label, Randomized, Prospective Study of Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Pathologic Myopia
Sponsor: Central Polyclinic of Internal Affairs of Ukraine
This NA trial investigates Pathologic Myopia and is currently ongoing. Central Polyclinic of Internal Affairs of Ukraine leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Apr 2022 — Apr 2024 [monthly]
Recruiting NA
-
Sep 2021 — Apr 2022 [monthly]
Recruiting NA
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Polyclinic of Internal Affairs of Ukraine
- Lesya Ukrainka Volyn National University
- Mykolaiv Region Ophthalmogical Hospital
- Odessa National Medical University
- The Filatov Institute of Eye Diseases and Tissue Therapy
For direct contact, visit the study record on ClinicalTrials.gov .